Human Epidermal Growth Factor Receptor 2 [ HER ‐2/neu] Amplification and Microsatellite Stable Status in Gastric and Gastroesophageal Adenocarcinoma: Assessing Frequency and Prognostic Implications at the Cancer Institute of Iran
Cancer Reports · 2025
DOI: 10.1002/cnr2.70314 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2025. Verfasst von Samaneh Salarvand und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Anatomical Pathology, Cancer Institute, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma, Erb-b2 Receptor Tyrosine Kinases, Esophageal Neoplasms. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tehran University of Medical Sciences and Health Services.
Abstract (Originalsprache)
Background
Molecular targeted therapy and immunotherapy have shown promise in managing gastric adenocarcinoma. The amplified expression of Human epidermal growth factor receptor‐2 (HER‐2) and microsatellite stable (MSI) status serve as indicators of response to targeted therapy and immunotherapy, respectively.
Aims
This study assessed the frequency of MSI status and HER‐2 expression in a pretreated sample of Iranian patients with gastric and gastroesophageal (GE) adenocarcinoma. Methods and Results We conducted HER‐2/neu expression and mismatch repair (MMR) system analyses on specimens from patients with gastric and GE adenocarcinoma at the Cancer Institute of Iran. Archival tissues from 135 mainly pre‐treated surgical specimens of gastric adenocarcinoma cases were used for HER‐2 analysis, and 66 specimens were used for MSI analysis. All specimens were tested for HER‐2 amplification, revealing that 11 patients (8.1%) had HER‐2 amplification, and three out of 66 examined patients exhibited MSI‐H. Patients with HER‐2 overexpressed specimens had a shorter median overall survival (OS) compared with HER‐2 negative cases (21 months (95% CI: 1.4–40.6) vs. 31 months (95% CI: 22.9–39), p = 0.18). The median disease‐free survival (DFS) for HER‐2 positive and negative patients was 15 and 28 months, respectively ( p = 0.25). The estimated median OS and DFS for patients with negative MSI were 26 and 20 months, respectively. However, none of the patients with MSI‐positive status experienced recurrence, metastases, or death within the follow‐up period; thus, MSI‐H patients had a significantly improved OS and DFS ( p = 0.018 and 0.020).
Conclusion
HER ‐2 expression, while less common in our Iranian population compared with North American or Western European countries, showed a nonsignificant trend toward poor outcomes in patients with gastric adenocarcinoma. MSI ‐H status was highly infrequent in our population, suggesting that immunotherapy may not be a beneficial treatment for a significant fraction of Iranian patients with gastric adenocarcinoma. However, a minority may still benefit from it. MSI ‐H was associated with reduced perineural invasion and improved OS and DFS . Therefore, this hypothesis warrants further investigation in clinical trials to underscore the prognostic significance of HER ‐2 and MSI status and the value of molecular profiling in guiding personalized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Anatomical Pathology, Cancer Institute, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Ophthalmology, School of Medicine, Ahvaz Joundishapur University of Medical Sciences, Ahvaz, Iran.
- Department of Radiation Oncology, Cancer Institute, IKHC, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Oncosurgery, Cancer Institute, IKHC, Tehran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Samaneh Salarvand, Abbas Mohammadi, Marzieh Lashkari, Amirmohsen Jalaeefar, Mohammad Shirkhoda, Romina Abyaneh, Reza Ghalehtaki
Förderung
- Tehran University of Medical Sciences and Health Services
Zitieren
APA
Salarvand, S., Mohammadi, A., Shahsiah, R., Bagheri, F., Gholizadeh, M., Jolany-Vangah, S., Esmati, E., Lashkari, M., Soleymani, V., Zareh-Dehabadi, S., Mehrtash, V., Jalaeefar, A., Shirkhoda, M., Toosang, M., Abyaneh, R., & Ghalehtaki, R. (2025). Human Epidermal Growth Factor Receptor 2 [ HER ‐2/neu] Amplification and Microsatellite Stable Status in Gastric and Gastroesophageal Adenocarcinoma: Assessing Frequency and Prognostic Implications at the Cancer Institute of Iran. Cancer Reports. https://doi.org/10.1002/cnr2.70314
Vancouver
Salarvand S, Mohammadi A, Shahsiah R, Bagheri F, Gholizadeh M, Jolany-Vangah S, et al. Human Epidermal Growth Factor Receptor 2 [ HER ‐2/neu] Amplification and Microsatellite Stable Status in Gastric and Gastroesophageal Adenocarcinoma: Assessing Frequency and Prognostic Implications at the Cancer Institute of Iran. Cancer Reports. 2025. doi:10.1002/cnr2.70314
BibTeX
@article{Salarvand2025,
author = {Salarvand, Samaneh and Mohammadi, Abbas and Shahsiah, Reza and Bagheri, Farzaneh and Gholizadeh, Mahsa and Jolany-Vangah, Somayeh and Esmati, Ebrahim and Lashkari, Marzieh and Soleymani, Vahid and Zareh-Dehabadi, Seraj and Mehrtash, Vahid and Jalaeefar, Amirmohsen and Shirkhoda, Mohammad and Toosang, Moones and Abyaneh, Romina and Ghalehtaki, Reza},
title = {Human Epidermal Growth Factor Receptor 2 [ HER ‐2/neu] Amplification and Microsatellite Stable Status in Gastric and Gastroesophageal Adenocarcinoma: Assessing Frequency and Prognostic Implications at the Cancer Institute of Iran},
journal = {Cancer Reports},
year = {2025},
doi = {10.1002/cnr2.70314}
}
EUVIMED